Intarcia Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Out of Business

  • Employees
  • 240

Employees

  • Latest Deal Type
  • Liquidation

Intarcia General Information

Description

Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of life. The company's proprietary subcutaneous delivery system comprises three unique technologies, including a stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, enabling patients to avail necessary treatment required for chronic serious disorders in the field of diabetes, obesity and autoimmune diseases.

Contact Information

Website
www.intarcia.com
Formerly Known As
BioMedicines
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • One Marina Park Drive
  • 13th Floor
  • Boston, MA 02210
  • United States
+1 (617)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Vertical(s)
Life Sciences
Corporate Office
  • One Marina Park Drive
  • 13th Floor
  • Boston, MA 02210
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intarcia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
22. Bankruptcy: Liquidation 01-Nov-2020 Completed Bankruptcy: Liquidation
21. Later Stage VC 14-Jan-2020 Completed Profitable
20. Later Stage VC (Series EE) 03-Aug-2017 Completed Profitable
19. Later Stage VC (Series DD) 01-May-2017 Completed Profitable
18. Later Stage VC (Series CC) 27-May-2016 Completed Profitable
17. Debt - General 06-May-2016 Completed Profitable
16. Later Stage VC (Series DD) 27-Mar-2014 Completed Clinical Trials - Phase 3
15. Later Stage VC (Series B2) Completed Clinical Trials - Phase 3
14. Later Stage VC (Series B1) $445M Completed Clinical Trials - Phase 3
13. Later Stage VC (Series AA) 08-Jan-2013 $445M Completed Clinical Trials - Phase 3
To view Intarcia’s complete valuation and funding history, request access »

Intarcia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series EE
Series DD
Series CC
Series BB3
Series BB2
Series BB1 3,833,865 $0.001000 8% $6 $6 1x $6 5.6%
Series AA 3,180,135 $0.001000 8% $6 $6 1x $6 4.64%
To view Intarcia’s complete cap table history, request access »

Intarcia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of lif
Drug Delivery
Boston, MA
240 As of 2018

Cleveland, OH
 

Vancouver, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intarcia Competitors (74)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Abeona Therapeutics Corporation Cleveland, OH
Genevant Corporate Backed or Acquired Vancouver, Canada
Triumvira Venture Capital-Backed Hamilton, Canada
Apellis Pharmaceuticals Formerly VC-backed Waltham, MA
StemiRNA Therapeutics Biotech Venture Capital-Backed Shanghai, China
You’re viewing 5 of 74 competitors. Get the full list »

Intarcia Patents

  • 640

    Total Documents Applications and Grants

  • Total Patents Families

  • 310

    Granted

  • 26

    Pending

  • Expiring in next 12 mo

Intarcia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220002371-A1 Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use Active 17-Apr-2020
US-11739134-B2 Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use Active 17-Apr-2020
US-20240166708-A1 Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use Pending 17-Apr-2020
EP-3864031-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018
CA-3116023-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018 C07K14/575
To view Intarcia’s complete patent history, request access »

Intarcia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intarcia Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Phoundry Pharmaceuticals 24-Sep-2015 Drug Discovery
Cytokinetics 01-Apr-2003 Pharmaceuticals
Cytokinetics 01-Nov-2000 Pharmaceuticals
Cytokinetics 01-Aug-1999 Early Stage VC Pharmaceuticals
To view Intarcia’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Intarcia Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Cytokinetics 01-Apr-2003 Completed
  • 11 buyers
Cytokinetics 01-Nov-2000 Completed
  • 6 buyers
Cytokinetics 01-Aug-1999 Early Stage VC Completed
  • 4 buyers
To view Intarcia’s complete exits history, request access »

Intarcia FAQs

  • When was Intarcia founded?

    Intarcia was founded in 1995.

  • Who is the founder of Intarcia?

    Mark Moran MD, David Franklin, Thomas Alessi Ph.D, and James Ahlers are the founders of Intarcia.

  • Where is Intarcia headquartered?

    Intarcia is headquartered in Boston, MA.

  • What is the size of Intarcia?

    Intarcia has 240 total employees.

  • What industry is Intarcia in?

    Intarcia’s primary industry is Drug Delivery.

  • Is Intarcia a private or public company?

    Intarcia is a Private company.

  • What is Intarcia’s current revenue?

    The current revenue for Intarcia is .

  • How much funding has Intarcia raised over time?

    Intarcia has raised $2.05B.

  • Who are Intarcia’s competitors?

    Abeona Therapeutics, Genevant, Triumvira, Apellis Pharmaceuticals, and StemiRNA Therapeutics Biotech are some of the 74 competitors of Intarcia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »